Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response

Tixagevimab/Cilgavimab for COVID-19 Pre-Exposure Prophylaxis in Hematologic Patients—A Tailored Approach Based on SARS-CoV-2 Vaccine Response

Patients with hematologic malignancies still face a significant risk of severe coronavirus disease 2019 (COVID-19). The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-neutralizing monoclonal antibody combination tixagevimab/cilgavimab (TIX/CGB) could be administered to immunocompr...

Full description

Bibliographic Details
Main Authors: Krischan Braitsch, Samuel D. Jeske, Jacob Stroh, Maike Hefter, Louise Platen, Quirin Bachmann, Lutz Renders, Ulrike Protzer, Katharina S. Götze, Peter Herhaus, Mareike Verbeek, Christoph D. Spinner, Florian Bassermann, Marion Högner, Bernhard Haller, Jochen Schneider, Michael Heider
Format: Article
Language:English
Published: MDPI AG 2024-08-01
Series:Vaccines
Subjects:
COVID-19
hematologic malignancy
tixagevimab/cilgavimab
neutralizing antibodies
PrEP
Online Access:https://www.mdpi.com/2076-393X/12/8/871

Internet

https://www.mdpi.com/2076-393X/12/8/871

Similar Items